Lates News

According to Every Economic AI Express, Huayuan Securities released a research report on October 30th, giving Pharmatrust (600276.SH) a "buy" rating. The main reasons for the rating include: 1) New products are being launched continuously, and the value of the innovative pipeline is continuously being realized; 2) The internationalization process is speeding up comprehensively, and overseas BD transactions may provide normalized profits. (Daily Economic News)